Eltanexor in Clinical Trials: A Promising Treatment for Relapsed or Refractory Blood Cancers

What is Eltanexor?

Eltanexor, also known by its research name KPT-8602, is an investigational medication being studied for the treatment of certain blood cancers1. It belongs to a class of drugs that work by affecting specific proteins in cancer cells, potentially causing these harmful cells to die or stop growing. Eltanexor is currently being evaluated in clinical trials and is not yet approved for general use outside of research settings.

What Conditions Can Eltanexor Treat?

Based on ongoing research, Eltanexor is being studied for the treatment of several serious blood disorders1:

• Myelodysplastic Syndrome (MDS) - A group of disorders where the bone marrow doesn't produce enough healthy blood cells. MDS can be relapsed (returned after a period of improvement) or refractory (not responding to standard treatments).
• Acute Myeloid Leukemia (AML) - A fast-growing cancer of the blood and bone marrow that affects the production of normal blood cells. Like MDS, AML can also be recurrent or refractory to treatment.

Specifically, Eltanexor is being investigated in patients whose disease has either come back after initial treatment (relapsed) or has not responded well to previous treatments (refractory)1. These patient populations often have limited treatment options, making new therapeutic approaches particularly important.

How Does Eltanexor Work?

Eltanexor works through a unique mechanism that involves trapping certain proteins, known as tumor suppressing proteins, within cancer cells1. These proteins normally help to control cell growth and prevent cancer. By keeping these beneficial proteins inside the cancer cells, Eltanexor may cause the cancer cells to die or stop dividing.

This approach differs from many traditional cancer treatments and represents a targeted strategy for addressing these difficult-to-treat blood cancers.

Current Clinical Research

Eltanexor is currently being studied in a Phase Ib clinical trial in combination with another medication called Venetoclax1. This study aims to:

• Establish the safe and biologically effective dose of Eltanexor when used together with Venetoclax
• Estimate how many patients achieve complete remission (disappearance of all signs of cancer)
• Assess the overall response rate (percentage of patients whose cancer shrinks or disappears)
• Measure how long patients survive overall
• Determine how long patients live without their disease getting worse (progression-free survival)
• Assess how long responses to treatment last

The research also includes exploratory objectives to better understand which patients might benefit most from this treatment combination1.

How is Eltanexor Administered?

In the current clinical trial, Eltanexor is given as an oral medication (taken by mouth) once per day for 5 days per week1. The treatment schedule may vary, with the medication being given for 14, 21, or 28 days each cycle, depending on the study protocol. Each complete cycle lasts 28 days (about 4 weeks).

When combined with Venetoclax, the treatment regimen involves:

• Eltanexor taken orally once daily for 5 days per week
• Venetoclax taken orally once daily on days 1-14 of each cycle

Patients continue receiving treatment cycles every 28 days as long as their disease doesn't worsen and they don't experience unacceptable side effects1.

Potential Side Effects

As with any medication, especially cancer treatments, Eltanexor may cause side effects. The current clinical trial is specifically designed to monitor and assess adverse events (side effects) that participants may experience1. These events are categorized and graded according to standardized criteria called the Common Terminology Criteria for Adverse Events (CTCAE).

While the specific side effect profile of Eltanexor is still being established through ongoing research, patients in the trial undergo regular monitoring to detect and manage any adverse effects that may occur.

Combination Therapy with Venetoclax

Eltanexor is being studied in combination with another medication called Venetoclax1. Venetoclax is a B-cell lymphoma-2 (BCL-2) inhibitor, which means it blocks a protein called Bcl-2 that helps cancer cells survive.

The rationale for combining these two medications is that they work through different mechanisms:

• Eltanexor traps tumor suppressing proteins within cancer cells
• Venetoclax blocks the Bcl-2 protein that cancer cells need for survival

By targeting cancer cells in two different ways, researchers hope this combination may be more effective than either medication alone for patients with relapsed or refractory MDS or AML1.

Patient Monitoring During Treatment

Patients receiving Eltanexor in clinical trials undergo comprehensive monitoring to track both their response to treatment and any potential side effects1. This monitoring includes:

• Bone marrow aspiration and biopsy - A procedure to collect and examine bone marrow samples to assess how the disease is responding to treatment
• Blood sample collection - Regular blood tests to monitor blood cell counts, liver and kidney function, and other important health parameters

After completing treatment, patients in the current study are followed for up to 24 months (2 years) with check-ups approximately every 3 months1. This long-term follow-up helps researchers understand the lasting effects of treatment and how durable the responses are.